TRABD2B: A Potential Drug Target and Biomarker (G388630)

Target Name: TRABD2B

NCBI ID: G388630

TRABD2B

TRABD2B: A Potential Drug Target and Biomarker

TRABD2B, also known as TRABD2B2, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is TRABD2B2, and it is a member of the TRABD2 family of proteins. This family of proteins is known for their role in the regulation of cell signaling pathways, specifically in the Wnt/FGF signaling pathway.

In recent years, researchers have been increasingly interested in studying TRABD2B as a potential drug target. This is because the TRABD2B protein has been shown to play a role in a variety of biological processes, including the development and progression of certain diseases.

One of the key reasons for the interest in TRABD2B as a drug target is its role in the regulation of the Wnt/FGF signaling pathway. This pathway is a well-established regulator of cell signaling pathways that is involved in many important biological processes, including the development and maintenance of tissues and organs.

Studies have shown that TRABD2B is involved in the regulation of the Wnt/FGF signaling pathway by interacting with its downstream effector, FGF-1. This interaction between TRABD2B and FGF-1 allows TRABD2B to regulate the activity of other genes that are involved in the Wnt/FGF signaling pathway.

Additionally, TRABD2B has also been shown to play a role in the regulation of the Shh gene, which is involved in the development and maintenance of many tissues, including the brain. Studies have shown that TRABD2B is involved in the regulation of Shh gene activity by interacting with its downstream effector, SMAD.

The potential benefits of targeting TRABD2B as a drug target are numerous. If TRABD2B is successfully targeted, it could potentially lead to the development of new treatments for a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Another potential benefit of targeting TRABD2B is its potential as a biomarker. TRABD2B is expressed in a variety of tissues and cells, including cancer cells, which makes it an attractive target for researchers to study as a biomarker. By measuring the levels of TRABD2B in cancer cells, researchers could potentially develop new diagnostic tests for cancer.

In addition to its potential as a drug target and biomarker, TRABD2B is also of interest to researchers due to its unique structure and biology. Unlike many other proteins, TRABD2B is a transmembrane protein, which means that it spans the cell membrane and is involved in the regulation of various processes that occur within the cell.

Furthermore, TRABD2B is a glycoprotein, which means that it is composed of both protein and carbohydrate. This unique structure is of particular interest to researchers because it allows for the study of the protein-carbohydrate interactions that occur between TRABD2B and its downstream effectors.

In conclusion, TRABD2B is a protein that has the potential to be a drug target and biomarker. Its role in the regulation of the Wnt/FGF signaling pathway and its expression in various tissues make it an attractive target for researchers. Additionally, its unique structure and biology make it an interesting study object in the fields of cancer research and neurodegenerative diseases.

Protein Name: TraB Domain Containing 2B

Functions: Metalloprotease that acts as a negative regulator of the Wnt signaling pathway by mediating the cleavage of the 8 N-terminal residues of a subset of Wnt proteins. Following cleavage, Wnt proteins become oxidized and form large disulfide-bond oligomers, leading to their inactivation. Able to cleave WNT3A, WNT5, but not WNT11. Required for head formation

The "TRABD2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRABD2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets